LakeShore Biopharma (LSB) Stock Statistics & Valuation Metrics

LakeShore Biopharma has a market cap or net worth of $34.37M. The enterprise value is ―.

LakeShore Biopharma has 41,212,692 shares outstanding. The number of shares has decreased by -2.65% in one year.

LakeShore Biopharma’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -9.15%.

The current PE Ratio of LakeShore Biopharma is ―. LakeShore Biopharma’s PEG ratio is ―.

In the last 12 months, LakeShore Biopharma had revenue of 614.96M and earned -99.98M in profits. Earnings per share was -0.94.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

LakeShore Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

LakeShore Biopharma upcoming earnings date is Jan 26, 2026, Before Open (Not Confirmed).

LakeShore Biopharma as a current ratio of 1.02, with Debt / Equity ratio of 82.92%

In the past 12 months, LakeShore Biopharma has paid -946.87K in taxes.

LakeShore Biopharma EV to EBITDA ratio is -7.96, with an EV/FCF ratio of -2.78.

LakeShore Biopharma has $246.35M in cash and marketable securities with $424.46M in debt, giving a net cash position of $178.11M billion.

Gross margin is 82.47%, with operating margin of -14.03%, and net profit margin of -16.26%.

The average price target for LakeShore Biopharma is $1.00, which is 11.43% higher than the current price. The consensus rating is Hold